Concinnity Genetics
AI-driven RNA design for gene therapy control.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £3.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Concinnity Genetics is a biotechnology company that spun out of the University of Edinburgh in 2023, specializing in improving the safety of cell and gene therapies. The company was co-founded by CEO Jessica Birt, a bioengineer with a background in computational biology and data science, and CSO Dr. Matthew Dale, who holds a PhD in Synthetic Biology. Both founders came from the University of Edinburgh's UK Centre for Mammalian Synthetic Biology. Their work received early support from Scottish Enterprise's High Growth Spinout Programme and they were twice winners at Scotland's Converge Challenge innovation competition.
The firm develops RNA-based gene control systems using a proprietary AI platform combined with synthetic biology expertise. This technology allows for the design and screening of large, complex libraries of RNA control systems, which aim to provide precise control over gene therapies after they have been administered to a patient. The primary benefit of these systems is the potential to increase therapeutic safety and efficacy by enabling therapies to dynamically adjust their activity, recognize specific tissue types, or reduce their own side effects. Concinnity's business model is centered on partnering with biopharmaceutical companies, offering its technology to help them design and optimize safer gene therapies. The company's goal is to become a key partner for gene control within the cell and gene therapy market.
In late 2024, Concinnity Genetics secured £3 million in an oversubscribed seed funding round. The investment was led by Eos Advisory and included participation from Scottish Enterprise, Maven Capital Partners, and the University of Edinburgh's venture fund, Old College Capital. This capital is intended to fund the establishment of its operations in Scotland's life sciences hub, initiate three new development programs for its control systems, and generate critical data to facilitate customer partnerships.
Keywords: gene therapy safety, RNA-based control systems, AI-driven RNA design, synthetic biology, cell therapy, gene control systems, therapeutic efficacy, post-dosing control, mammalian synthetic biology, bioengineering, computational biology, biopharmaceutical partnerships, gene engineering, drug design, biotechnology, Edinburgh spinout, venture capital, life sciences, gene expression, precision medicine